Kazia Therapeutics Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
KZIA Nasdaq 2830 www.kaziatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Kazia Therapeutics Limited

Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer - Jul 28th, 2026 5:30 am
Kazia Therapeutics Appoints James Levine as Chief Financial Officer - Jun 2nd, 2026 5:30 am
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer - May 26th, 2026 5:30 am
How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform - Apr 28th, 2026 11:30 am
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform - Apr 15th, 2026 6:00 am
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - Apr 13th, 2026 3:05 pm
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) - Jan 30th, 2026 6:00 am
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer - Jan 27th, 2026 6:00 am
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End - Jan 8th, 2026 7:00 am
US Equity Futures Mixed Pre-Bell Monday Despite Oil Sector Surge - Jan 5th, 2026 6:51 am
Kazia Therapeutics Regains Full Nasdaq Listing Compliance - Dec 22nd, 2025 6:00 am
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+ - Dec 10th, 2025 6:00 am
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities - Dec 2nd, 2025 7:00 am
Traders Await Nvidia Earnings, Fed Minutes, Driving Narrow Premarket Gains for US Equity Futures - Nov 19th, 2025 7:08 am
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy - Nov 18th, 2025 2:15 pm
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - Oct 27th, 2025 5:15 am
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program - Oct 7th, 2025 6:30 am
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen - Oct 2nd, 2025 6:30 am
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG - Oct 1st, 2025 7:21 am
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy - Sep 11th, 2025 6:00 am